Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.78 and traded as low as $0.76. Vaxart shares last traded at $0.78, with a volume of 895,348 shares traded.

Analyst Ratings Changes

Separately, Oppenheimer began coverage on shares of Vaxart in a research note on Thursday, August 15th. They set an "outperform" rating and a $4.00 price target for the company.

Vaxart Stock Performance

The stock has a market cap of $137.58 million, a price-to-earnings ratio of -1.47 and a beta of 0.66. The stock's 50 day moving average is $0.85 and its two-hundred day moving average is $0.78.

Vaxart (NASDAQ:VXRT - Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. The firm had revenue of $6.40 million during the quarter, compared to analyst estimates of $65.70 million. During the same quarter last year, the business posted ($0.16) EPS. On average, sell-side analysts predict that Vaxart, Inc. will post -0.47 EPS for the current year.

Institutional Trading of Vaxart

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC lifted its stake in shares of Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock worth $2,660,000 after acquiring an additional 2,095,274 shares during the period. Monaco Asset Management SAM acquired a new stake in shares of Vaxart in the 2nd quarter worth $402,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Vaxart in the 2nd quarter worth $65,000. RA Capital Management L.P. purchased a new position in shares of Vaxart in the 1st quarter valued at about $20,000,000. Finally, Tidal Investments LLC purchased a new position in shares of Vaxart in the 1st quarter valued at about $56,000. Institutional investors and hedge funds own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.